JP2021517114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517114A5 JP2021517114A5 JP2020544574A JP2020544574A JP2021517114A5 JP 2021517114 A5 JP2021517114 A5 JP 2021517114A5 JP 2020544574 A JP2020544574 A JP 2020544574A JP 2020544574 A JP2020544574 A JP 2020544574A JP 2021517114 A5 JP2021517114 A5 JP 2021517114A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- immune response
- cd11b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 5
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 3
- 102100022338 Integrin alpha-M Human genes 0.000 claims 3
- 102000002689 Toll-like receptor Human genes 0.000 claims 3
- 108020000411 Toll-like receptor Proteins 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000000066 myeloid cell Anatomy 0.000 claims 1
- 244000309459 oncolytic virus Species 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- 239000003970 toll like receptor agonist Substances 0.000 claims 1
Claims (9)
- 細胞上のＣＤ１１ｂのＩ−ドメインに特異的に結合する試薬を含む、免疫応答を調節することによるがんの治療における使用のための
医薬組成物。 - 前記ＣＤ１１ｂは腫瘍関連骨髄系細胞（ＴＡＭＣ）上にある
請求項１に記載の医薬組成物。 - 前記試薬は、ＣＤ１１ｂのＩ−ドメインを結合する抗体である
請求項１または２に記載の医薬組成物。 - 免疫応答調節剤をさらに含む
請求項１または２に記載の医薬組成物。 - 前記免疫応答調節剤は、ＰＤ−１、ＰＤ−Ｌ１、ＣＴＬＡ４、ＣＤ４０、ＯＸ４０またはＴｏｌｌ様受容体（ＴＬＲ）に特異的に結合する試薬である
請求項４に記載の医薬組成物。 - 前記免疫応答調節剤は、抗ＰＤ−１抗体、抗ＰＤ−Ｌ１抗体、抗ＣＴＬＡ４抗体、抗ＣＤ４０抗体、抗ＯＸ４０抗体、Ｔｏｌｌ様受容体アゴニスト、腫瘍溶解性ウイルス、放射線療法または化学療法剤である
請求項３に記載の医薬組成物。 - 前記免疫応答調節剤は抗ＣＴＬＡ４抗体である
請求項３に記載の医薬組成物。 - 前記Ｔｏｌｌ様（ＴＬＲ）受容体アゴニストはＣｐＧである
請求項６に記載の医薬組成物。 - 前記化学療法剤はタキソールである
請求項６に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581632P | 2017-11-03 | 2017-11-03 | |
| US62/581,632 | 2017-11-03 | ||
| PCT/US2018/059247 WO2019177669A1 (en) | 2017-11-03 | 2018-11-05 | Method for modulation of tumor associated myeloid cells and enhancing immune checkpoint blockade |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517114A JP2021517114A (ja) | 2021-07-15 |
| JP2021517114A5 true JP2021517114A5 (ja) | 2021-12-16 |
| JP7407721B2 JP7407721B2 (ja) | 2024-01-04 |
Family
ID=67907109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544574A Active JP7407721B2 (ja) | 2017-11-03 | 2018-11-05 | 腫瘍関連骨髄系細胞の調節および免疫チェックポイント遮断の増強のための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20200255531A1 (ja) |
| EP (1) | EP3703677A4 (ja) |
| JP (1) | JP7407721B2 (ja) |
| KR (1) | KR20200083990A (ja) |
| CN (1) | CN111615386A (ja) |
| AU (1) | AU2018413352A1 (ja) |
| CA (1) | CA3080974A1 (ja) |
| RU (1) | RU2020118134A (ja) |
| TW (1) | TWI805656B (ja) |
| WO (1) | WO2019177669A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210128725A1 (en) * | 2019-11-04 | 2021-05-06 | Northwestern University | Cytotoxic lipid particles targeted to tumor-associated myeloid cells (tamcs) and synergized with radiation therapy for treating glioblastoma |
| KR102488525B1 (ko) * | 2020-08-19 | 2023-01-13 | 국립암센터 | 비흡연성 비소세포 폐암 환자의 면역상태 판단용 바이오마커 및 이를 이용한 비흡연성 비소세포 폐암 환자의 면역 상태에 대한 정보를 제공하는 방법 |
| WO2023170633A1 (en) * | 2022-03-10 | 2023-09-14 | Mendus B.V. | Use of modified cells of leukemic origin and pd-l1 antibody for enhancing the efficacy of cancer cell therapy |
| WO2023235504A2 (en) * | 2022-06-01 | 2023-12-07 | Syncromune, Inc. | A method for the treatment of cancer via tumor cell lysis and intratumoral administration of combinations of immunotherapeutic ingredients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2331348T3 (es) * | 2000-09-15 | 2009-12-30 | Pasteur Institut | Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b. |
| SI1503794T1 (sl) * | 2002-04-12 | 2012-09-28 | Medarex Inc | Postopek zdravljenja z uporabo ctla-4 antiteles |
| WO2005070120A2 (en) * | 2004-01-09 | 2005-08-04 | Serologicals Investment Company, Inc. | Cell culture media |
| FR2954703B1 (fr) * | 2009-12-28 | 2013-12-13 | Chu Nantes | Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes |
| AU2013248972A1 (en) * | 2012-04-20 | 2014-11-13 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
| WO2014159923A1 (en) * | 2013-03-13 | 2014-10-02 | Health Research, Inc. | Enhancement of vaccines |
| CN107949571A (zh) * | 2015-06-12 | 2018-04-20 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 调控免疫反应的方法及抗体 |
-
2018
- 2018-11-05 JP JP2020544574A patent/JP7407721B2/ja active Active
- 2018-11-05 AU AU2018413352A patent/AU2018413352A1/en active Pending
- 2018-11-05 KR KR1020207014272A patent/KR20200083990A/ko not_active Application Discontinuation
- 2018-11-05 US US16/761,259 patent/US20200255531A1/en not_active Abandoned
- 2018-11-05 CN CN201880071798.5A patent/CN111615386A/zh active Pending
- 2018-11-05 RU RU2020118134A patent/RU2020118134A/ru unknown
- 2018-11-05 WO PCT/US2018/059247 patent/WO2019177669A1/en unknown
- 2018-11-05 CA CA3080974A patent/CA3080974A1/en active Pending
- 2018-11-05 EP EP18910077.9A patent/EP3703677A4/en active Pending
- 2018-12-06 TW TW107144004A patent/TWI805656B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517114A5 (ja) | ||
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2013231054A5 (ja) | ||
| JP2018522887A5 (ja) | ||
| EA202191457A1 (ru) | Анти-pd-l1/анти-4-1bb биспецифические антитела и их применения | |
| RU2016107426A (ru) | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета | |
| JP2019525957A5 (ja) | ||
| MX2023006482A (es) | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador. | |
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| WO2016145085A3 (en) | Cd27 agonists | |
| RU2016143383A (ru) | Иммуноактивирующая антигенсвязывающая молекула | |
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| JP2016531907A5 (ja) | ||
| RU2020118134A (ru) | Способ модуляции опухолеассоциированных миелоидных клеток и улучшения блокады иммунных контрольных точек | |
| GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| EA201990183A1 (ru) | Аденовирус, вооруженный биспецифичным активатором т-клеток (bite) | |
| JP2018532383A5 (ja) | ||
| WO2016029073A3 (en) | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody | |
| JP2020502147A5 (ja) | ||
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| JP2019501151A5 (ja) | ||
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения |